DOI: 10.36347/sjams.2021.v09i09.029

Pages: 1466-1469

The number of individuals suffered from depression is constantly increasing worldwide. The antidepressant monoaminergic hypothesis has dominated the pathophysiology of mood disorders and the development of novel treatment strategies for long years, but the discovery of the antidepressant action of ketamine and these metabolites has opened a new way for discovering a fast antidepressant but without reducing side effects. The target of fast and best tolerated antidepressant appears difficult but close.